First-line treatment of advanced ovarian cancer: current research and perspectives
- 10 January 2010
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Anticancer Therapy
- Vol. 10 (1), 47-60
- https://doi.org/10.1586/era.09.167
Abstract
Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival. To date, intensive surgical staging and cytoreduction, followed by primary chemotherapy with the carboplatin-paclitaxel regimen, are considered the gold standard for the management of this disease. Nevertheless, despite good initial response to systemic therapy after optimal debulking surgery, the long-term survival remains poor, with a high risk of recurrence. Furthermore, medical therapy of ovarian cancer impacts quality of life owing to the common occurrence of chemotherapy side effects, such as alopecia, neurotoxicity and fatigue. In order to improve the efficacy and reduce the toxicity of first-line chemotherapy, more than 10,000 women have been involved in worldwide randomized trials in the last 10 years. Several treatment alternatives have been investigated, such as intraperitoneal chemotherapy, alternative doublets and triplet regimens, in the effort to find an optimal first-line treatment strategy. In this review we discuss the results of these trials, the recent progresses and the most important ongoing studies, including those with emerging target and biological agents.Keywords
This publication has 81 references indexed in Scilit:
- Pharmaceutical Management of Ovarian CancerDrugs, 2008
- Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 2006
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trialsBritish Journal of Cancer, 1998
- Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancerGynecologic Oncology, 1992
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989
- Intraperitoneal Cisplatin with Intravenous Cyclophosphamide and Doxorubicin for Previously Untreated Stage III and IV Ovarian CarcinomaCancer Investigation, 1989
- Acute Nonlymphocytic Leukemia after Therapy with Alkylating Agents for Ovarian CancerNew England Journal of Medicine, 1982